NKARTA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.42 USD | +1.90% |
|
-13.99% | -3.56% |
| May. 09 | Nkarta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 26 | Canaccord Genuity Adjusts Nkarta's Price Target to $16 From $15, Keeps Buy Rating | MT |
Presenter SpeechDingding Shi (Analysts)Good afternoon, everyone. My name is Kelly Shi, one of ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of patients with autoimmune diseases or hematologic malignancies. It is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. Both product candidates enable an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies. Its NKX019 oncology program is based on the potential to treat a variety of B-cell malignancies by targeting the CD19 antigen that is reliably expressed on these types of cancerous cells. Its NKX101 program is designed to enhance the power of innate NK cell biology to detect and kill cancerous cells.
Calendar
2024-06-12
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
6.3
USD
Average target price
19.25
USD
Spread / Average Target
+205.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.56% | 444M | |
| +3.90% | 108B | |
| +11.13% | 104B | |
| +1.28% | 22.33B | |
| -12.89% | 22.19B | |
| -7.05% | 18.69B | |
| -38.36% | 17.74B | |
| -9.85% | 17.64B | |
| +3.56% | 14.05B | |
| +37.09% | 12.51B |
- Stock Market
- Equities
- NKTX Stock
- News Nkarta, Inc.
- Transcript : Nkarta, Inc. Presents at Jefferies 2021 Virtual Healthcare Conference, Jun-02-2021 03
